Pressure from governments to lower drug prices risks undermining medical innovation, Bayer AG's chief executive said on Wednesday, echoing complaints of other drug company executives. Speaking at the Boston College Chief Executives' Club, Marijn Dekkers said there was "tremendous pressure" on drugmakers to lower prices. "The danger of pushing the prices of prescription drugs down, down, down is that at some point the business model of developing these drugs will lose its attractiveness," he said.